Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599

Journal of Clinical Oncology

Volumn 25, Issue 4, 2007, Pages 418-423

  Langer, Corey J ^a   Li, Sigui ^a   Schiller, Joan ^a   Tester, William ^a   Rapoport, Bernardo L ^a   Johnson, David H ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; WEIGHT REDUCTION; DISEASE COURSE; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS;

EID: 33846985986     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.9452     Document Type: Article

References (22)

1. Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25-32, 1980
2. Albain K, Crowley J, LeBlanc M, et al: Survival determinants in extensive-stage non-small lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9:1618-1626, 1991
3. Paesmans M, Sculier JP, Libert P, et al: Prognostic factors for survival in advanced non-small cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 13:1221-1230, 1995
4. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
5. Le Chevalier T, Brisgand D, Soria JC, et al: Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplain to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. The Oncologist 6:8-11, 2001 (suppl 1)
6. Cullen MH, Billingham LJ, Woodroffe CM, et al: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 17:3188-3194, 1999
7. Billingham L, Cullen M: The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann Oncol 12:1671-1675, 2001
8. Vansteenkiste J, Vandebroek J, Nackaerts K, et al: Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: Detailed symptom analysis of a randomized study comparing cisplatin-vindesine to gemcitabine. Lung Cancer 40:191-199, 2003
9. Ruckdeschel J, Finkelstein D, Ettinger D, et al: A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 4:14-22, 1986
10. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92-98, 2002
11. Sweeney C, Zhu J, Sandler A, et al: Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A phase III trial in metastatic non-small cell lung carcinoma. Cancer 92:2639-2647, 2001
12. Alberola V, Camps C, Provencio M, et al: Cisplatin plus gemcitabine versus a cisplatin-based triplet versus non-platinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21:3207-3213, 2003
13. Smit EF, van Meerbeeck JP, Lianes P, et al: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21:3909-3917, 2003
14. Kosmidis P, Mylonakis N, Nicolaides C, et al: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial. J Clin Oncol 20:3578-3585, 2002
15. Jiroutek M, Johnson D, Blum R, et al: Prognostic factors in advanced non-small cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981-1992. Proc Am Soc Clin Oncol 17:461, 1998 (abstr 1774)
16. Frasci G, Lorusso V, Panza N, et al: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 18:2529-2536, 2000
17. Gridelli C, Perrone F, Gallo C, et al: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372, 2003
18. Lilenbaum RC, Herndon J, List M, et al: Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol 21:1a, 2002 (abstr 2)
19. Kosimidis PA, Dimopoulos MA, Syrigos C, et al: Gemcitabine vs gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and PS 2: A prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 23:627, 2004 (suppl; abstr 7058)
20. Hesketh PJ, Chansky K, Lau DH, et al: Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2: A SWOG phase II trial (S0027). J Clin Oncol 23:627, 2004 (suppl; abstr 7056)
21. Lilenbaum R, Rubin M, Samuel J, et al: A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 23:627, 2004 (suppl; abstr 7057)
22. Kelly K: Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status. Semin Oncol 31:3-7, 2004 (suppl 6)